294 related articles for article (PubMed ID: 26788460)
1. Update on immunoglobulin a nephropathy. Part II: Clinical, diagnostic and therapeutical aspects.
Salvadori M; Rosso G
World J Nephrol; 2016 Jan; 5(1):6-19. PubMed ID: 26788460
[TBL] [Abstract][Full Text] [Related]
2. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
Li S; Li JP
Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
[TBL] [Abstract][Full Text] [Related]
3. Update on treatment of immunoglobulin A nephropathy.
Zhang YM; Zhang H
Nephrology (Carlton); 2018 Oct; 23 Suppl 4():62-67. PubMed ID: 30298661
[TBL] [Abstract][Full Text] [Related]
4. A Personalized Update on IgA Nephropathy: A New Vision and New Future Challenges.
Gutiérrez E; Carvaca-Fontán F; Luzardo L; Morales E; Alonso M; Praga M
Nephron; 2020; 144(11):555-571. PubMed ID: 32818944
[TBL] [Abstract][Full Text] [Related]
5. Con: STOP immunosuppression in IgA nephropathy.
Rauen T; Eitner F; Fitzner C; Floege J
Nephrol Dial Transplant; 2016 Nov; 31(11):1771-1774. PubMed ID: 27515693
[TBL] [Abstract][Full Text] [Related]
6. IgA Vasculitis and IgA Nephropathy: Same Disease?
Pillebout E
J Clin Med; 2021 May; 10(11):. PubMed ID: 34070665
[TBL] [Abstract][Full Text] [Related]
7. Pro: STOP immunosuppression in IgA nephropathy?
Pozzi C
Nephrol Dial Transplant; 2016 Nov; 31(11):1766-1770. PubMed ID: 27515694
[TBL] [Abstract][Full Text] [Related]
8. Clinical and histological features and therapeutic strategies for IgA nephropathy.
Moriyama T
Clin Exp Nephrol; 2019 Sep; 23(9):1089-1099. PubMed ID: 30968243
[TBL] [Abstract][Full Text] [Related]
9. An Update on Targeted Treatment of IgA Nephropathy: An Autoimmune Perspective.
Huang X; Xu G
Front Pharmacol; 2021; 12():715253. PubMed ID: 34497518
[TBL] [Abstract][Full Text] [Related]
10. A pilot and comparative study between pathological and serological levels of immunoglobulin and complement among three kinds of primary glomerulonephritis.
Dong J; Peng T; Gao J; Jia X; Yan G; Wang Y
BMC Immunol; 2018 Jun; 19(1):18. PubMed ID: 29925312
[TBL] [Abstract][Full Text] [Related]
11. After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy.
Rauen T; Wied S; Fitzner C; Eitner F; Sommerer C; Zeier M; Otte B; Panzer U; Budde K; Benck U; Mertens PR; Kuhlmann U; Witzke O; Gross O; Vielhauer V; Mann JFE; Hilgers RD; Floege J;
Kidney Int; 2020 Oct; 98(4):1044-1052. PubMed ID: 32450154
[TBL] [Abstract][Full Text] [Related]
12. IgA Nephropathy: Core Curriculum 2021.
Pattrapornpisut P; Avila-Casado C; Reich HN
Am J Kidney Dis; 2021 Sep; 78(3):429-441. PubMed ID: 34247883
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppressive agents for treating IgA nephropathy.
Vecchio M; Bonerba B; Palmer SC; Craig JC; Ruospo M; Samuels JA; Molony DA; Schena FP; Strippoli GF
Cochrane Database Syst Rev; 2015 Aug; (8):CD003965. PubMed ID: 26235292
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive agents for treating IgA nephropathy.
Natale P; Palmer SC; Ruospo M; Saglimbene VM; Craig JC; Vecchio M; Samuels JA; Molony DA; Schena FP; Strippoli GF
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD003965. PubMed ID: 32162319
[TBL] [Abstract][Full Text] [Related]
15. Has The Time Arrived to Refine The Indications of Immunosuppressive Therapy and Prognosis in IgA Nephropathy?
Obrișcă B; Sinescu I; Ismail G; Mircescu G
J Clin Med; 2019 Oct; 8(10):. PubMed ID: 31581654
[TBL] [Abstract][Full Text] [Related]
16. Non-immunosuppressive treatment for IgA nephropathy.
Reid S; Cawthon PM; Craig JC; Samuels JA; Molony DA; Strippoli GF
Cochrane Database Syst Rev; 2011 Mar; (3):CD003962. PubMed ID: 21412884
[TBL] [Abstract][Full Text] [Related]
17. The Treatment of IgA Nephropathy.
Lai KN; Leung JC; Tang SC
Kidney Dis (Basel); 2015 May; 1(1):19-26. PubMed ID: 27536661
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for IgA nephropathy in children.
Vaz de Castro PAS; Bitencourt L; Pereira BWS; Lima AQR; Hermida HS; Moreira Neto CR; Mestriner MD; Simões E Silva AC
Pediatr Nephrol; 2022 Mar; 37(3):499-508. PubMed ID: 34686915
[TBL] [Abstract][Full Text] [Related]
19. Present and future therapy options in IgA-nephropathy.
Floege J; Eitner F
J Nephrol; 2005; 18(4):354-61. PubMed ID: 16245237
[TBL] [Abstract][Full Text] [Related]
20. Application of Oxford classification, and overexpression of transforming growth factor-β1 and immunoglobulins in immunoglobulin A nephropathy: correlation with World Health Organization classification of immunoglobulin A nephropathy in a Chinese patient cohort.
Meng H; Zhang L; E X; Ye F; Li H; Han C; Yamakawa M; Jin X
Transl Res; 2014 Jan; 163(1):8-18. PubMed ID: 23891568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
